Greenwich LifeSciencesGLSI -7.17%33 PB Ratio is 60.97 as of Jul. 02, 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,230 Biotechnology companies, Greenwich LifeSciences ranks worse than 98.13% on this metric.
The historical rank and industry rank for Greenwich LifeSciences's PB Ratio or its related term are showing as below:
GLSI'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 66.02
Current: 61.11
During the past 8 years, Greenwich LifeSciences's highest PB Ratio was 66.02. The lowest was 0.00. And the median was 0.00.
GLSI's PB Ratio is ranked worse than 98.13% of 1230
companies
in the Biotechnology industry
Industry Median: 2.95
vs GLSI: 61.11
During the past 12 months, Greenwich LifeSciences's average Book Value Per Share Growth Rate was -63.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -71.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -61.20% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Greenwich LifeSciences was -37.90% per year. The lowest was -71.00% per year. And the median was -67.70% per year.
Back to Basics: PB Ratio
Greenwich LifeSciences (NAS:GLSI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Greenwich LifeSciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Greenwich LifeSciences (GLSI) has a PB Ratio of 60.97 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Greenwich LifeSciences and its competitors. According to the industry distribution chart, Greenwich LifeSciences ranks #1207 out of 1230 companies in the Biotechnology industry, placing it in the top 98.1%.
Is Greenwich LifeSciences' PB Ratio too high?
Greenwich LifeSciences' current PB Ratio is 60.97. The Biotechnology industry median PB Ratio is 2.95. Greenwich LifeSciences' value of 60.97 is 1966.8% above this industry median. Based on the distribution chart, Greenwich LifeSciences ranks #1207 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' PB Ratio compare to SABS and SRZN?
According to the Biotechnology industry distribution chart, Greenwich LifeSciences ranks #1207 out of 1230 companies for PB Ratio. This places Greenwich LifeSciences in the lower half of its industry. The industry median PB Ratio is 2.95. Greenwich LifeSciences' value of 60.97 is 1966.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenwich LifeSciences's current PB Ratio of 60.97 is 1966.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Greenwich LifeSciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenwich LifeSciences's current PB Ratio is 60.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current PB Ratio of 60.97. The current PB Ratio is 60.97 and 1966.8% above the Biotechnology industry median of 2.95. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current PB Ratio is 60.97 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score
Get the complete analysis for GLSI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLSI has been successfully added to your 
